Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Survival impact of unexpected N2 in stage IIIB/N2 non-small cell lung cancer patients

Survival impact of unexpected N2 in stage IIIB/N2 non-small cell lung cancer patients BackgroundWe investigated the effect of unexpected N2 on survival in stage IIIB/N2 cases.MethodsWe retrospectively analyzed 1803 non-small cell lung cancer patients between 2010 and 2016. There were 89 patients (4.9%) with unexpected N2 (pathological (p) IIIB/N2 group), whereas 49 patients (2.7%) with cN2 (clinical (c) IIIB/N2 group). Although pIIIB/N2 group underwent surgery followed by adjuvant therapy, the cIIIB/N2 group of patients had multimodality treatment including induction chemotherapy ± radiotherapy followed by surgery.ResultsThe five-year overall survival (OS) for all patients was 36.0% [median survival time (MST) 27.9 months], and disease-free survival (DFS) was 28.9% (MST, 18.2 months). The OS was 39.6% (MST: 34.4 months) and the median DFS time was 31.1% (Median: 23.1 months) in the pIIIB/N2 group, whereas it was 29.2% (MST: 23.0 months) for OS and 22% (median: 12.4 months) for DFS in the cIIIB/N2 group. There were no significant OS and DFS differences between the pIIIB/N2 group and the cIIIB/N2 group (p = 0.124 and p = 0.168, respectively).ConclusionsIn stage IIIB/N2 cases, the fact that N2 could not be detected preoperatively with minimally invasive or invasive methods and was detected in the pathological examination after surgery does not provide a survival advantage. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asian Cardiovascular and Thoracic Annals SAGE

Survival impact of unexpected N2 in stage IIIB/N2 non-small cell lung cancer patients

Download PDF
6 pages

Loading next page...
 
/lp/sage/survival-impact-of-unexpected-n2-in-stage-iiib-n2-non-small-cell-lung-Z1rhoFor75
Publisher
SAGE
Copyright
© The Author(s) 2023
ISSN
0218-4923
eISSN
1816-5370
DOI
10.1177/02184923231151503
Publisher site
See Article on Publisher Site

Abstract

BackgroundWe investigated the effect of unexpected N2 on survival in stage IIIB/N2 cases.MethodsWe retrospectively analyzed 1803 non-small cell lung cancer patients between 2010 and 2016. There were 89 patients (4.9%) with unexpected N2 (pathological (p) IIIB/N2 group), whereas 49 patients (2.7%) with cN2 (clinical (c) IIIB/N2 group). Although pIIIB/N2 group underwent surgery followed by adjuvant therapy, the cIIIB/N2 group of patients had multimodality treatment including induction chemotherapy ± radiotherapy followed by surgery.ResultsThe five-year overall survival (OS) for all patients was 36.0% [median survival time (MST) 27.9 months], and disease-free survival (DFS) was 28.9% (MST, 18.2 months). The OS was 39.6% (MST: 34.4 months) and the median DFS time was 31.1% (Median: 23.1 months) in the pIIIB/N2 group, whereas it was 29.2% (MST: 23.0 months) for OS and 22% (median: 12.4 months) for DFS in the cIIIB/N2 group. There were no significant OS and DFS differences between the pIIIB/N2 group and the cIIIB/N2 group (p = 0.124 and p = 0.168, respectively).ConclusionsIn stage IIIB/N2 cases, the fact that N2 could not be detected preoperatively with minimally invasive or invasive methods and was detected in the pathological examination after surgery does not provide a survival advantage.

Journal

Asian Cardiovascular and Thoracic Annals – SAGE

Published: Mar 1, 2023

Keywords: Stage IIIB; unexpected N2; advanced stage; neoadjuvant therapy; lung cancer

References

  • The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer
    Asamura, H; Chansky, K; Crowley, J
  • Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?
    Collaud, S; Provost, B; Besse, B
  • Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases
    Casali, C; Stefani, A; Natali, P
  • 18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer: state of the art
    Castello, A; Rossi, S; Lopci, E
  • Cancer statistics
    Siegel, RL; Miller, KD; Jemal, A
  • Staging IASLC, Prognostic Factors Committee, Advisory Boards and Participating Institutions. IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eight edition of the TNM classification for lung cancer
    Rami-Porta, R; Bolejack, V; Crowley, J
  • Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
    Spigel, DR; Faivre-Finn, C; Gray, JE
  • Prognostic factors and survival in patients undergoing surgery for T4 nonsmall cell lung carcinoma
    Citak, N; Büyükkale, S; Sayar, A
  • Long term and disease-free survival following surgical resection of occult N2 lung cancer
    Kirmani, BH; Volpi, S; Aresu, G
  • Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications
    Andre, F; Grunenwald, D; Pignon, JP
  • Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease)
    Goldstraw, P; Mannam, GC; Kaplan, DK
  • Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer
    Van Klaveren, RJ; Festen, J; Otten, HJ
  • Overall survival characterization of incidental N2 non-small cell lung cancer over 14 years at a single Canadian institution
    Van der Merwe, C; D’Silva, A; Otsuka, S
  • Is the prognosis of occult N2 disease similar to that of positive positron emission tomography-computed tomography (PET/CT) scan single-station N2 disease in patients with non-small cell lung cancer treated by surgical resection?
    Honguero Martínez, AF; García Jiménez, MD; García Vicente, A
  • How effective is neoadjuvant therapy followed by surgery for pathologic single-station N2 non-small cell lung cancer?
    Keshava, HB; Tan, KS; Dycoco, J
  • Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer
    Cho, HJ; Kim, SR; Kim, HR
  • Treatment strategy for patients with surgically discovered N2 stage IIIA non-small cell lung cancer
    Nakanishi, R; Osaki, T; Nakanishi, K